Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market
By Diagnosis (Pelvic Examination, Ultrasound, Blood Test),
By Drug Class (Oral Contraceptives, Insulin Sensitizing Agents, Antiandrogens, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Others),
By Distribution and Usage (Hospitals, Pharmacies, and Drug Stores, e-commerce, Clinics),
By Surgery (Wedge Resection, Laparoscopic Drilling),
By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa):
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market - Global Analysis and Forecast 2023-2033
The global polycystic ovarian syndrome/disease (PCOS/PCOD) market showcased a revenue of USD 3,101.6 Million in 2022 and is projected to witness a compounded annual growth rate (CAGR) of more than 4% over the forecast period of 2023-2033.
Russia-Ukraine War Impact
Market Scope
About the Market
Impact of COVID-19
Global Economic Slowdown
Market Dynamics
Driver
Restrain
Opportunity
Recent Developments
Synopsis
How is this report helpful
FAQ's
Report Coverage
Related Reports
PCOS is a gynecological condition characterized by abnormal hormone levels required for ovulation and the maintenance of secondary sexual characteristics in women. The ovaries are the primary organs of the female reproductive system. The ovaries perform several functions in the female body, including egg production and hormone secretion. Estrogen, progesterone, and a trace of testosterone are all secreted by the ovaries. The key drivers of the polycystic ovarian syndrome therapeutics market include increased PCOS prevalence, higher patient population understanding, and the growing use of combination therapy.
The PCOS market is expanding, causing a rise in the incidence of PCOS, better patient consciousness, and higher usage of standard therapy. Insulin is essential to maintain normal blood sugar levels. As a result, more insulin is secreted, leading to hyperinsulinemia, a major factor in developing PCOS. Increased insulin levels in the blood stimulate the manufacture of androgens such as testosterone. Approximately 80% of PCOS patients have insulin resistance. Since this disease has many repercussions, several medications and treatments are available. As a result, industry leaders are driving the development of breakthrough treatments and therapies. Additionally, the massive rise of PCOS drugs and technological advancements in PCOS testing all have a significant positive impact on the market expansion.
The global demand for PCOS medications provides several opportunities for industry participants to grow. Pharmaceutical businesses are concentrating on rising economies in Asia Pacific and Africa, such as Kenya and Nigeria, to access a large patient population. Consequently, improved reimbursement laws and lower drug costs for PCOS therapy are expected to increase global PCOS treatment utilization. However, increased R&D expenditure increases government initiatives to raise awareness of PCOS. It is expected to drive the market throughout the projection period.
Impact of Russia-Ukraine War on Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market
The war between Russia and Ukraine could have repercussions for healthcare, such as delays in medical supply lines and hospital overpopulation. Hospital and clinic infrastructure collapse will have an impact on healthcare systems, resulting in hospital staff fleeing and hospitals coping with increased patient safety. As a result, many towns are constantly attacked, and Ukraine lacks proper hospitals and doctors. As a result, most medical treatments in Ukraine have been halted, hindering polycystic ovarian syndrome or disease market growth.
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD): Market Scope
The polycystic ovarian syndrome/disease (PCOS/pcod) market is divided into four segments PCOS/PCOD Diagnosis, PCOD/PCOS Drug Class, PCOD/PCOS Distribution and Usage, and PCOD/PCOS Surgery. Furthermore, these segments are subdivided into respective categories and cross-referenced to North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa for regional analysis. The PCOS/PCOD Diagnosis segment is further categorized into Pelvic Examination, Ultrasound, and Blood Test. The PCOD/PCOS Drug Class segment is segregated into Oral Contraceptives, Insulin Sensitizing Agents, Antiandrogens, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, and Others. The PCOD/PCOS Distribution and Usage segment of the Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) market is bifurcated by Hospitals, Pharmacies, Drug Stores, E-Commerce, and Clinics. With respect to PCOD/PCOS Surgery, the industry is analyzed by Wedge Resection and Laparoscopic Drilling. Each of these segments is further classified into regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The historical dataset of 2018-2022 is provided in the report, whereas the forecast period of 2023-2033 is offered.
Ultrasound will capture the highest market share within the diagnosis segment
The ultrasound market within the PCOS/PCOD diagnosis segment will witness the highest market share within the forecast period of 2023-2033; the factors responsible for market growth, such as the occurrence of polycystic ovaries, are detected and documented via ultrasound. However, since PCOS is a syndrome, the existence of polycystic ovaries is inadequate for diagnosis. Additionally, An ultrasound can create a picture of the uterus, ovaries, and pelvis. The image depicts whether or not the ovaries contain 'cysts' (partially formed eggs) and whether or not an ovary is swollen. It is also beneficial for monitoring the uterine lining (endometrium), which can thicken if periods are irregular, increasing the risk of womb cancer in women.
The oral Contraceptives segment will witness the highest growth rate between 2023-2033
The market for oral contraceptive tablets is also expected to expand quickly. Drospirenone, medroxyprogesterone acetate, and Ethinyl estradiol are the most commonly available commercially accessible oral contraceptives. Furthermore, Oral contraceptives protect women from uterine (uterus) hyperplasia and cancer by regulating the regular menstrual cycle. Hirsutism and acne can also be treated with oral contraceptives. Oral contraceptive pills, commonly known as hormonal medications, can be taken to avoid pregnancy. This is among the most widely used methods of birth control. If taken correctly, these pills can be up to 99.9% efficient. Additionally, various OCPs are commonly used to treat Polycystic ovarian syndrome symptoms such as skipped or delayed menstrual cycles, severe period pain, Premenstrual syndrome (PMS), and acne. As a result, demand for OCPs is predicted to grow at the fastest rate over the period.
The Hospitals segment will capture the highest market share in the coming years
The hospital sector is expected to lead the global PCOS medications market in terms of revenue growth. This segment's significant proportion can also be attributed to the affordability of therapies and treatments for the more expensive aspects of PCOS care, such as long-term metabolic medical problems (type-2 diabetes) or reproductive issues such as infertility, abnormal uterine bleeding, menstrual dysfunction, and hirsutism, within hospitals. Furthermore, medicines and therapy techniques are usually given by doctors; as a result of this, hospitals have a larger proportion of the market distribution channels.
Laparoscopic Drilling segment within the application to witness the highest CAGR during the forecast timeframe
The fastest-growing segment is likely to be laparoscopic ovarian drilling. Laparoscopic ovarian drilling is a surgical treatment that can help with ovulation in women with polycystic ovary syndrome (PCOS). Electrocautery or a laser is used to kill parts of the ovaries. Moreover, laparoscopic ovarian drilling is one of the most frequent surgeries performed by surgeons in emergency conditions. Although PCOS is a leading cause of infertility in women and therapeutic response deteriorates over time, abdominal surgery with a thin microscope is routinely used. Furthermore, these surgeries are one-time treatments, as opposed to fertility medications, which must be used every month.
Asia Pacific to capture the highest market share in the Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market
The Asia-Pacific region is expected to be the fastest-expanding market for ovarian syndrome. The market is anticipated to expand due to the increased incidence of diabetes in women, lifestyle changes, and the rise in obesity among women. This provides a good environment for the market to expand. Additionally, several countries governments are aiming to lower the rising prevalence of PCOS through activities that aid in PCOS diagnosis and treatment, as well as necessary lifestyle changes. These elements are projected to boost the Asia Pacific market in the coming years. Moreover, India and China have the greatest populations in the Asia Pacific. The nation's PCOS treatment company has excellent prospects due to the presence of a big target patient demographic.
Impact of COVID-19 on Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Industry
The risk of severe COVID-19 to PCOS-related conditions such as hyperinflammation, insufficient vitamin D levels, and hyperandrogenism. Furthermore, this typical female patient population has a surprisingly high incidence of several cardio-metabolic disorders, such as type 2 diabetes, overweight, and hypertension, which may considerably increase the risk of COVID-19-related outcomes. Furthermore, with the COVID-19 pandemic infection, respective governments decided to impose lockdown and social distancing regulations, resulting in the suspension of multiple operations, distribution network disruptions, limiting business growth, and the suspension of developments, all of which had a negative impact on the polycystic ovarian syndrome or disease market.
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) : Market Dynamics
The market dynamics section of the report covers an in-depth analysis of drivers and restraints opportunities impacting the polycystic ovarian syndrome/disease (PCOS/pod) market. The report also encompasses major market strategies practiced by the industry, followed by patent analysis, product analysis, competitive benchmarking of companies, PORTER and PESTLE analysis of polycystic ovarian syndrome/disease (PCOS/pcod) industry, pricing analysis, and geographic competitiveness to provide a detailed understanding. The major players operating the market are Allergan, Apothecus Pharmaceutical Cor, Amgen, Blairex Laboratories Inc, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, JSC BIOCAD, Novartis A, Pfizer, and Teva Pharmaceutical Industries. These companies cumulatively hold most of the polycystic ovarian syndrome/disease (PCOS/PCOD) market share and actively undergoes strategic development, such as new product launches, mergers, collaborations, business expansions, acquisitions, and long-term contracts to ensure market penetration. These companies also largely focus on research and development to gain technological competitiveness in the market. A detailed analysis of these companies is offered in the report.
Driver: Women are becoming more aware of the risks of PCOS.
The numerous risks to women's health, particularly reproductive health, posed by ovarian syndrome are improving women's knowledge of the disorder's preventive measures. Moreover, for instance, the PCOS Awareness Association (PCOSAA) organizes a number of activities and meetings to raise public awareness among a wider audience. PCOSSA recently announced PCOS awareness month and has organized a number of activities and events to raise public awareness. According to the Centers for Disease Control and Prevention, PCOS is a prevalent cause of infertility in women, affecting around 6% to 12% of females, or approximately 5 million women in the United States. The growing awareness of PCOS facilitates a better understanding & diagnosis of the disorder's signs, which include irregular or no menstrual, hair growth, acne, and irregular ovulation.
Restrain: Strict Drug Approval Regulations
The lack of FDA-approved pharmaceuticals is expected to hinder the growth of the global polycystic ovary syndrome therapy market. In addition, the lack of licensed treatments and FDA medication approval is expected to be a challenge to the polycystic ovarian syndrome (PCOS) medication market. There are presently no FDA or EMA-approved drugs for the direct treatment of polycystic ovaries. As a result, doctors can only prescribe drugs for off-label uses. The FDA removed sibutramine (a sympathomimetic core appetite suppressant) from the United States market in 2017 due to concerns about increased CVD events associated with its use. Additionally, rimonabant, an important appetite suppressant cannabinoid CB1 receptor antagonist, wasn't authorized in the United States due to fears regarding drug overdoses. Additionally, adopting alternative treatment modalities, including Ayurveda and Homeopathic, is expected to hinder the growth of the global polycystic ovarian syndrome treatment market.
Opportunity: Increasing Incidence of PCOS Disorders
A growing percentage of Indian women are thought to be affected by PCOS. If not treated promptly, the disorder can have major health effects. PCOS has become more frequent in past decades. Even though the exact cause of the polycystic ovarian syndrome is undetermined. PCOS is associated with the development of several problems, including diabetes, cardiovascular disease, and several other hormone-related illnesses. The major health issues associated with polycystic ovary syndrome need a growing need for the disorder's elimination, which would be expected to significantly drive future market growth. Moreover, the latest technologies in polycystic ovary syndrome detection and increased awareness of polycystic ovary syndrome therapy are expected to provide profitable prospects for the market.
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market: Recent Developments
- In January 2023, Celmatix Inc., a biotechnology company focused on ovarian biology, reported today the achievement of a fourth milestone in its five-year, multi-target cooperation with Evotec. Evotec and Bayer AG reached the milestone by moving a second therapeutic program focusing on a novel Celmatix-identified drug target toward hit identification.
- In January 2023, Spruce Biosciences, Inc., a late-stage biopharmaceutical company that focuses on researching and commercializing novel therapies for rare endocrine disorders with a significant unmet medical need, provided a status report on its clinical programmers, predicted forthcoming milestones, and overall strategy for advancing tildacerfont in CAH and polycystic ovary syndrome (PCOS).
- In January 2020, Evotec SE and Bayer AG launched a new five-year, multi-target collaboration to develop various clinical candidates fortreatingf polycystic ovarian syndrome.
- In June 2021, Allara was a New York-based early-stage firm that aims to help women better manage polycystic ovarian syndrome or PCOS. Women suffering from reproductive and hormonal disorders may experience irregular periods, infertility, or gestational diabetes, as well as acne, weight gain, and excessive hair growth. And it is much from uncommon, affecting one in every ten women of childbearing age.
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market: Synopsis
The polycystic ovarian syndrome/disease (PCOS/pod) market study offers revenue and growth data sets of segments provided at the global, regional, and country levels. The report offers the historical data set of 2018-2022 and the forecast period of 2023-2033. For the purpose of analysis, Quadrant Market Insights (QMI) has segregated the polycystic ovarian syndrome/disease (PCOS/PCOD) market into four major segments as follows:
By Diagnosis
- Pelvic Examination
- Ultrasound
- Blood Test
By Drug Class
- Oral Contraceptives
- Insulin Sensitizing Agents
- Antiandrogens
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Others
By Distribution and Usage
- Hospitals
- Pharmacies and Drug Stores
- e-commerce
- Clinics
By Surgery
- Wedge Resection
- Laparoscopic Drilling
The regional analysis of the polycystic ovarian syndrome/disease (PCOS/PCOD) market is as follows:
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Russia
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Chile
Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Israel
Key players operating in the polycystic ovarian syndrome/disease (PCOS/PCOD) industry are:
- Allergan
- Apothecary Pharmaceutical
- Amgen
- Blairex Laboratories Inc
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc
- JSC BIOCAD
- Novartis
- Pfizer
- Teva Pharmaceutical Industries
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market: Who Should Purchase, and How It Will Help Readers
- The report is best suited for top-level decision-makers, individuals who are supposed to take a leadership role or require market research to start a business, independent researchers, research institutes, and anyone who wishes to gain detailed strategic insights into the polycystic ovarian syndrome/disease (PCOS/PCOD) market.
- This report provides a qualitative and quantitative analysis of the market segments, current trends, estimations, and dynamics of the polycystic ovarian syndrome/disease (PCOS/PCOD) market analysis from 2018 to 2033 to identify the prevailing market opportunities.
- Market research and information related to key drivers, restraints, and opportunities are offered.
- Porter's five forces and PESTLE analysis highlight the potency of buyers and suppliers to enable stakeholders' market profit-oriented business decisions and strengthen their supplier-buyer network.
- An in-depth analysis of the polycystic ovarian syndrome/disease (PCOS/PCOD) segmentation assists in determining the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes an analysis of the regional and global polycystic ovarian syndrome/disease (PCOS/PCOD) industry trends, key players, market segments, application areas, and market growth strategies.
- The report offers insights from primary interviews and CXOs of major industry players. It also offers a comprehensive contact and event repository to ensure future collaborations among industry stakeholders.
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market: Frequently Asked Questions (FAQ)
Q: How big is the polycystic ovarian syndrome/disease (PCOS/PCOD) market?
A: The global polycystic ovarian syndrome/disease (PCOS/PCOD) market showcased a revenue of USD 3,101.6 million in 2022 and is projected to witness a compounded annual growth rate (CAGR) of more than 4% over the forecast period of 2023-2033.
Q: Does the report have several polycystic ovarian syndrome/disease (PCOS/PCOD) numbers bifurcated by segments and regions?
A: The report offers a total number of polycystic ovarian syndrome/disease (PCOS/PCOD) market , further bifurcated into segments and regions. Please refer to the TOC page for more information.
Q: What are the major trends in the polycystic ovarian syndrome/disease (PCOS/PCOD) market?
A:Increasing awareness about the PCOD/PCOS syndrome with more individual treating it as a normal situations to support the market opportunities in developing and under developed regions.
Q: How can I get the sample Report on the polycystic ovarian syndrome/disease (PCOS/PCOD) market?
A: The polycystic ovarian syndrome/disease (PCOS/PCOD) market report sample can be obtained on demand from the website. Also, 24*7 chat support and direct call services are provided to procure the sample report
Q: Is it possible to purchase a specific or customized report as per my needs
A: Yes, it is possible to purchase a specific part of the report or edit the scope of the report at your convenience. Feel free to drop us the mail/talk to our customer support or schedule a conversation to procure a customized report.
Report Coverage
- Diagnosis
- Drug Class
- Distribution and Usage
- Surgery
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
- Rising awareness about the risks of PCOD/PCOS in women across the globe
- Increasing detection of disorders related to PCOD/PCOS
- Limitations for usage of several drugs across regions, limiting business opportunities
Allergan, Apothecus Pharmaceutical Cor, Amgen, Blairex Laboratories Inc, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, JSC BIOCAD, Novartis A, Pfizer, Teva Pharmaceutical Industries
1. Introduction
1.1 Report Description
1.1.1 Definition
1.1.2 Abbreviations
1.2 Key Market Segments
1.3 Benefits to Stakeholders
1.4 Research Methodology
1.4.1 Market Scoping
1.4.1.1 Problem Identification
1.4.1.2 Defining the Market
1.4.2 Market Estimation
1.4.2.1 Data Mining
1.4.2.2 Product Analysis
1.4.2.3 Application Analysis
1.4.2.4 Market Engineering and Forecasting
1.4.2.4.1 Bottom-up Demand Side
1.4.2.4.2 Bottom-up Supply side
1.4.3 Market Authentication
1.4.3.1 Data Triangulation
1.4.3.1.1 Top-down Supply Side
1.4.3.1.2 Top-down Demand Side
1.4.3.1.3 Data Triangulation
1.4.3.2 Primary Insights and Industry feedback
1.4.4 Report Writing
2. Executive Summary
2.1 Market Snapshot
2.2 Macro Trends, Global Economic Factors and Import/Export Insights
2.3 Primary Insights
2.4 PCOD/PCOS Diagosis Insights
2.5 PCOD/PCOS Drug Class Insights
2.6 PCOD/PCOS Distribution & Usage Insights
2.7 PCOD/PCOS Surgery Insights
2.8 Regional Insights
3. Market Overview
3.1 Market Segment and Scope
3.2 Top Investment Pockets
3.3 Key Strategic Initiatives
3.4 Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market Industry Ecosystem
3.5 Market Evolution
3.6 Patent Analysis
3.7 Technology Landscape
3.8 Regulatory Infrastructure
3.9 Porter’s Analysis
3.9.1 Bargaining Power of Buyer
3.9.2 Bargaining Power of Supplier
3.9.3 Threat of New Entrants
3.9.4 Threat of Substitutes
3.9.5 Industry Rivalry
3.10 PESTLE Analysis
3.11 Market Dynamics
3.11.1 Drivers
3.11.2 Restrains
3.11.3 Opportunities
3.12 Impact of COVID-19 on Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market
3.13 Russia-Ukraine War Impact on Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market
3.14 Growth Share Matrix
3.15 Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market Quadrant
4. Polycystic Ovarian Disease/Syndrome (PCOD/PCOS) Market, By Diagnosis
4.1 Major Impacting Factors, By Diagnosis
4.1.1 Key Market Trends and Growth Factors
4.1.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
4.1.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
4.2 Pelvic Examination
4.2.1 Key Market Trends and Growth Factors
4.2.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
4.2.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
4.3 Ultrasound
4.3.1 Key Market Trends and Growth Factors
4.3.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
4.3.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
4.4 Blood Test
4.4.1 Key Market Trends and Growth Factors
4.4.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
4.4.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
5. Polycystic Ovarian Disease/Syndrome (PCOD/PCOS) Market, By Drug Class
5.1 Major Impacting Factors, By Drug Class
5.1.1 Key Market Trends and Growth Factors
5.1.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
5.1.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
5.2 Oral Contraceptives
5.2.1 Key Market Trends and Growth Factors
5.2.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
5.2.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
5.3 Insulin Sensitizing Agents
5.3.1 Key Market Trends and Growth Factors
5.3.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
5.3.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
5.4 Antiandrogens
5.4.1 Key Market Trends and Growth Factors
5.4.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
5.4.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
5.5 Ornithine Decarboxylase Inhibitors
5.5.1 Key Market Trends and Growth Factors
5.5.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
5.5.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
5.6 Aromatase Inhibitors & SERMs
5.6.1 Key Market Trends and Growth Factors
5.6.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
5.6.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
5.7 Others
5.7.1 Key Market Trends and Growth Factors
5.7.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
5.7.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
6. Polycystic Ovarian Disease/Syndrome (PCOD/PCOS) Market, By Distribution and Usage
6.1 Major Impacting Factors, By Distribution and Usage
6.1.1 Key Market Trends and Growth Factors
6.1.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
6.1.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
6.2 Hospitals
6.2.1 Key Market Trends and Growth Factors
6.2.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
6.2.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
6.3 Pharmacies and Drug Stores
6.3.1 Key Market Trends and Growth Factors
6.3.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
6.3.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
6.4 e-commerce
6.4.1 Key Market Trends and Growth Factors
6.4.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
6.4.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
6.5 Clinics
6.5.1 Key Market Trends and Growth Factors
6.5.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
6.5.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
7. Polycystic Ovarian Disease/Syndrome (PCOD/PCOS) Market, By Surgery
7.1 Major Impacting Factors, By Surgery
7.1.1 Key Market Trends and Growth Factors
7.1.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
7.1.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
7.2 Wedge Resection
7.2.1 Key Market Trends and Growth Factors
7.2.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
7.2.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
7.3 Laparoscopic Drilling
7.3.1 Key Market Trends and Growth Factors
7.3.2 Market Size and Forecast, by Region, 2018-2033, (USD Million)
7.3.3 Market Size and Forecast, by Country, 2018-2033, (USD Million)
8. Polycystic Ovarian Disease/Syndrome (PCOD/PCOS) Market, By Region
8.1 Global Market Trends and Growth Factors
8.2 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.3 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.4 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.5 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.6 Market Size and Forecast, by Region, 2018-2033, (USD Million)
8.7 North America
8.7.1 Key Market Trends and Growth Factors
8.7.2 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.7.3 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.7.4 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.7.5 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.7.6 Market Size and Forecast, by Country, 2018-2033, (USD Million)
8.7.7 U.S.
8.7.7.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.7.7.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.7.7.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.7.7.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.7.8 Canada
8.7.8.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.7.8.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.7.8.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.7.8.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.7.9 Mexico
8.7.9.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.7.9.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.7.9.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.7.9.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.8 Europe
8.8.1 Key Market Trends and Growth Factors
8.8.2 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.8.3 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.8.4 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.8.5 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.8.6 Market Size and Forecast, by Country, 2018-2033, (USD Million)
8.8.7 UK
8.8.7.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.8.7.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.8.7.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.8.7.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.8.8 Germany
8.8.8.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.8.8.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.8.8.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.8.8.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.8.9 France
8.8.9.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.8.9.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.8.9.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.8.9.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.8.10 Russia
8.8.10.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.8.10.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.8.10.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.8.10.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.8.11 Italy
8.8.11.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.8.11.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.8.11.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.8.11.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.8.12 Rest of Europe
8.8.12.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.8.12.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.8.12.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.8.12.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.9 Asia-Pacific
8.9.1 Key Market Trends and Growth Factors
8.9.2 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.9.3 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.9.4 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.9.5 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.9.6 Market Size and Forecast, by Country, 2018-2033, (USD Million)
8.9.7 China
8.9.7.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.9.7.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.9.7.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.9.7.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.9.8 India
8.9.8.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.9.8.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.9.8.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.9.8.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.9.9 Japan
8.9.9.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.9.9.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.9.9.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.9.9.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.9.10 Australia
8.9.10.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.9.10.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.9.10.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.9.10.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.9.11 Rest of Asia-Pacific
8.9.11.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.9.11.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.9.11.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.9.11.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.10 Latin America
8.10.1 Key Market Trends and Growth Factors
8.10.2 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.10.3 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.10.4 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.10.5 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.10.6 Market Size and Forecast, by Country, 2018-2033, (USD Million)
8.10.7 Brazil
8.10.7.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.10.7.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.10.7.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.10.7.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.10.8 Argentina
8.10.8.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.10.8.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.10.8.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.10.8.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.10.9 Mexico
8.10.9.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.10.9.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.10.9.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.10.9.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.10.10 Chile
8.10.10.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.10.10.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.10.10.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.10.10.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.11 Middle East and Africa
8.11.1 Key Market Trends and Growth Factors
8.11.2 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.11.3 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.11.4 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.11.5 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.11.6 Market Size and Forecast, by Country, 2018-2033, (USD Million)
8.11.7 South Africa
8.11.7.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.11.7.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.11.7.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.11.7.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.11.8 UAE
8.11.8.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.11.8.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.11.8.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.11.8.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.11.9 Saudi Arabia
8.11.9.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.11.9.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.11.9.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.11.9.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
8.11.10 Israel
8.11.10.1 Market Size and Forecast, by Diagnosis, 2018-2033, (USD Million)
8.11.10.2 Market Size and Forecast, by Drug Class, 2018-2033, (USD Million)
8.11.10.3 Market Size and Forecast, by Distribution and Usage, 2018-2033, (USD Million)
8.11.10.4 Market Size and Forecast, by Surgery, 2018-2033, (USD Million)
9. Competitive Benchmarking & Company Profiles
9.1 Competitive Benchmarking
9.1.1 Company Market Share
9.1.2 Product Mapping
9.1.3 Competitive Heat map
9.2 Allergan
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Product Offering
9.2.4 Strategic Initiatives
9.2.5 SWOT
9.2.6 Ansoff Matrix
9.3 Apothecus Pharmaceutical Cor
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Product Offering
9.3.4 Strategic Initiatives
9.3.5 SWOT
9.3.6 Ansoff Matrix
9.4 Amgen
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Product Offering
9.4.4 Strategic Initiatives
9.4.5 SWOT
9.4.6 Ansoff Matrix
9.5 Blairex Laboratories Inc
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Product Offering
9.5.4 Strategic Initiatives
9.5.5 SWOT
9.5.6 Ansoff Matrix
9.6 Bristol-Myers Squibb Company
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Product Offering
9.6.4 Strategic Initiatives
9.6.5 SWOT
9.6.6 Ansoff Matrix
9.7 Johnson & Johnson Services, Inc
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Product Offering
9.7.4 Strategic Initiatives
9.7.5 SWOT
9.7.6 Ansoff Matrix
9.8 JSC BIOCAD
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Product Offering
9.8.4 Strategic Initiatives
9.8.5 SWOT
9.8.6 Ansoff Matrix
9.9 Novartis A
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Product Offering
9.9.4 Strategic Initiatives
9.9.5 SWOT
9.9.6 Ansoff Matrix
9.10 Teva Pharmaceutical Industries
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Product Offering
9.10.4 Strategic Initiatives
9.10.5 SWOT
9.10.6 Ansoff Matrix
9.11 Teva Pharmaceutical Industries
9.11.1 Company Overview
9.11.2 Financial Analysis
9.11.3 Product Offering
9.11.4 Strategic Initiatives
9.11.5 SWOT
9.11.6 Ansoff Matrix
10. Industry Connects and Upcoming Seminars
